Publications by authors named "Nirmaljeet Singh Malhi"

6 Publications

  • Page 1 of 1

Lower Gastrointestinal Bleeding: Liver Rams into Gut!

GE Port J Gastroenterol 2019 May 27;26(3):218-220. Epub 2018 Apr 27.

Department of Gastroenterology and Liver Disease, SPS Hospital, Ludhiana, India.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1159/000488605DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528081PMC
May 2019

Baffling Cause of Upper Gastrointestinal Bleeding!

GE Port J Gastroenterol 2019 Mar 27;26(2):142-144. Epub 2018 Apr 27.

Department of Gastroenterology and Liver Disease, SPS Hospital, Ludhiana, India.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1159/000488604DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6454382PMC
March 2019

Central retinal vein occlusion revealing celiac disease: The first report of two cases from India.

Indian J Ophthalmol 2018 09;66(9):1315-1317

Department of Cataract and Refractive Surgery, Dhami Eye Care Hospital, Ludhiana, Punjab, India.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijo.IJO_351_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113809PMC
September 2018

Treatment of chronic hepatitis C genotype 3 with Sofosbuvir-based therpy: a real-life study.

Hepatol Int 2017 May 31;11(3):277-285. Epub 2017 Mar 31.

Himalayan Institute of Medical Sciences, Dehradun, UttarKhand, India.

Background And Aims: Recently, Sofosbuvir was launched in India at affordable cost. We conducted a real-life study to determine the efficacy and safety of Sofosbuvir plus Ribavirin, with and without peginterferon-alfa 2a, in patients with chronic hepatitis C (CHC) genotype 3, the commonest genotype in South Asia.

Methods: This study included data of CHC patients from 11 sites in northern India between March 2015 and December 2015 (n = 1203). Patients with CHC genotype 3 (n = 931), who were treated with either Sofosbuvir 400 mg plus weight-based Ribavirin, daily ×24 weeks (n = 432) (dual therapy), or Peginterferon-α2a 180 mcg weekly, Sofosbuvir 400 mg plus weight-based Ribavirin, daily ×12 weeks (n = 499) (triple therapy) were included for analysis. Primary outcome was the proportion of patients achieving sustained viral response at 12 weeks post-therapy.

Results: The overall SVR rates were 91 and 92% in the dual and triple therapy arms, respectively. The SVR rates in treatment experienced were 67 and 74% versus 93 and 96% in naïve patients, on the dual and triple therapy arms, respectively. The SVR rates of cirrhotics were 73 and 75% on the dual and triple treatment arms, respectively. The SVR rates were low in the experienced cirrhotic patients: 44% (dual therapy) and 58% (triple therapy). Common adverse events were fatigue, headache, and myalgia.

Conclusion: Both dual and triple therapy regimes resulted in SVR rates of >95% in CHC genotype 3 who were naive non-cirrhotics. However, the SVR rates were low in treatment-experienced cirrhotics.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12072-017-9794-1DOI Listing
May 2017

Pancreatic ascites treated by endoscopic pancreatic sphincterotomy alone: a case report.

Gastrointest Endosc 2003 May;57(6):802-4

Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1067/mge.2003.221DOI Listing
May 2003